Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reducing transplant toxicity.

L Feinstein1, R Storb

  • 1Program in Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.

Current Opinion in Hematology
|October 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistent socioeconomic and racial and ethnic disparities in pathogen burden in the United States, 1999-2014.

Epidemiology and infection·2019
Same author

The impact of pathogen burden on leukocyte telomere length in the Multi-Ethnic Study of Atherosclerosis.

Epidemiology and infection·2017
Same author

Determination of nicotinic acid and riboflavin in multi-vitamin tablets.

Journal of the American Pharmaceutical Association. American Pharmaceutical Association·2010
Same author

Dietary patterns related to attainment in school: the importance of early eating patterns.

Journal of epidemiology and community health·2008
Same author

Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.

Annals of the New York Academy of Sciences·2001
Same author

Nonmyeloablative hematopoietic cell transplantation.

Current opinion in oncology·2001
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

New transplant strategies aim to reduce toxicity and improve graft-versus-tumor effects. These approaches may expand treatment options for more patients needing allogeneic hematopoietic cell transplantation.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Conventional myeloablative allogeneic hematopoietic cell transplantation (HCT) is associated with significant morbidity and mortality.
  • This limits its application to younger, healthier patients.
  • T-cell-mediated graft-versus-tumor (GVT) effects are crucial for eradicating malignancy post-HCT.

Purpose of the Study:

  • To explore strategies for reducing regimen-related toxicities in allogeneic HCT.
  • To optimize graft-versus-tumor effects while minimizing treatment-related complications.
  • To expand eligibility for allogeneic HCT to a broader patient population.

Main Methods:

  • Investigating reduced-intensity HCT regimens.
  • Developing minimally myelosuppressive HCT regimens.

Related Experiment Videos

  • Utilizing immunosuppression to facilitate allogeneic engraftment and GVT effects.

    • Main Results:

    • Preliminary results from reduced-intensity and minimally myelosuppressive strategies are encouraging.
    • These novel approaches aim to balance engraftment, GVT effects, and toxicity.
    • Short follow-up periods are a limitation in current assessments.

    Conclusions:

    • New HCT strategies show promise in reducing toxicity and enhancing GVT effects.
    • Challenges remain in optimizing regimens for full donor engraftment and minimizing graft-versus-host disease (GVHD).
    • Successful long-term efficacy could significantly broaden HCT accessibility for ineligible patients.